More Targeted Use of Cancer Drugs: First EU Project Integrates Pharmacogenomics into Tumor Boards
The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective. The National Center for Tumor Diseases (NCT) in Heidelberg is contributing extensive expertise and data to the project.